Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications
- PMID: 17185467
- DOI: 10.1182/blood-2006-07-034678
Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications
Abstract
Adenosine deaminase (ADA) deficiency is a systemic metabolic disease that causes an autosomal recessive variant of severe combined immunodeficiency (SCID) and less consistently other complications including neurologic abnormalities. Hematopoietic stem cell transplantation (HSCT) is able to correct the immunodeficiency, whereas control of nonimmunologic complications has not been extensively explored. We applied HSCT in 15 ADA-deficient patients consecutively treated at our institutions since 1982 and analyzed long-term outcome. Seven patients received transplants without conditioning from HLA-matched family donors (MFDs); the other 8 patients received conditioning and were given transplants either from HLA-mismatched family donors (MMFDs; n = 6) or from matched unrelated donors (MUDs; n = 2). At a mean follow-up period of 12 years (range, 4-22 years), 12 patients are alive with stable and complete immune reconstitution (7 of 7 after MFD, 4 of 6 after MMFD, and 1 of 2 after MUD transplantation). Six of 12 surviving patients show marked neurologic abnormalities, which include mental retardation, motor dysfunction, and sensorineural hearing deficit. We were unable to identify disease or transplantation-related factors correlating with this divergent neurologic outcome. The high rate of neurologic abnormalities observed in long-term surviving patients with ADA deficiency indicates that HSCT commonly fails to control CNS complications in this metabolic disease.
Similar articles
-
Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.Blood. 2012 Oct 25;120(17):3615-24; quiz 3626. doi: 10.1182/blood-2011-12-396879. Epub 2012 Jul 12. Blood. 2012. PMID: 22791287
-
Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.J Clin Immunol. 2017 Aug;37(6):582-591. doi: 10.1007/s10875-017-0421-7. Epub 2017 Jul 26. J Clin Immunol. 2017. PMID: 28748310
-
Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.J Clin Immunol. 2020 Nov;40(8):1124-1131. doi: 10.1007/s10875-020-00857-9. Epub 2020 Sep 2. J Clin Immunol. 2020. PMID: 32880085 Free PMC article.
-
How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).J Clin Immunol. 2017 May;37(4):351-356. doi: 10.1007/s10875-017-0373-y. Epub 2017 Feb 14. J Clin Immunol. 2017. PMID: 28194615 Review.
-
Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.J Allergy Clin Immunol. 2019 Mar;143(3):852-863. doi: 10.1016/j.jaci.2018.08.024. Epub 2018 Sep 5. J Allergy Clin Immunol. 2019. PMID: 30194989 Free PMC article. Review.
Cited by
-
Clinical applications of gene therapy for primary immunodeficiencies.Hum Gene Ther. 2015 Apr;26(4):210-9. doi: 10.1089/hum.2015.047. Hum Gene Ther. 2015. PMID: 25860576 Free PMC article. Review.
-
Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.Immunol Res. 2009;44(1-3):150-9. doi: 10.1007/s12026-009-8107-8. Immunol Res. 2009. PMID: 19224139
-
Gene therapy on the move.EMBO Mol Med. 2013 Nov;5(11):1642-61. doi: 10.1002/emmm.201202287. Epub 2013 Sep 17. EMBO Mol Med. 2013. PMID: 24106209 Free PMC article. Review.
-
Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency.Blood. 2011 Sep 8;118(10):2688-94. doi: 10.1182/blood-2011-01-329359. Epub 2011 Jul 1. Blood. 2011. PMID: 21725047 Free PMC article.
-
Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.Biol Blood Marrow Transplant. 2012 Sep;18(9):1438-45. doi: 10.1016/j.bbmt.2012.03.003. Epub 2012 Mar 16. Biol Blood Marrow Transplant. 2012. PMID: 22430083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials